Radiopharmaceutical manufacturer Fuzionaire Diagnostics (Fuzionaire Dx) has joined with McGill University and the Montreal Neurological Institute-Hospital in a research agreement to develop new ways for detecting and treating neurodegenerative diseases.
Professionals from McGill and The Neuro will offer their expertise in nuclear medicine and clinical imaging to enable Fuzionaire Dx’s chemistry-driven discovery platform to produce radiopharmaceuticals that localize and image abnormal brain tissue for safe and affordable, noninvasive diagnostic tests that can be used to detect diseases such as Alzheimer’s, Parkinson’s and traumatic brain injury.